- +1-315-215-1633
- sales@thebrainyinsights.com
The global Diabetic Neuropathy market was valued at USD 4.17 Billion in 2023 and growing at a CAGR of 6.8% from 2024 to 2033. The market is expected to reach USD 8.04 Billion by 2033. Diabetic neuropathy is a common complication of diabetes mellites, which causes the weakening of sensory, motor and autonomic nerves. It leads to neuropathic pain, autonomic dysfunction, foot ulcers and decreased quality of life. Diabetic neuropathy has its clinical impact, but it still remains underdiagnosed and undertreated. In 2022, based on the CDC, around 37.3 million or 11.3% of the US population were suffering from diabetes. That more than 57% have diabetic neuropathy, and the total prevalence of Diabetic painful neuropathy (DPN) is around 15% of the diabetic population, which is considered the main cause of neuropathic pain. Some of the most common complications of diabetes are diabetic neuropathy and ischemia. Also, it was found that around 60% of the people suffering from diabetic neuropathy can develop diabetic foot ulcers (DFU). These factors are driving the treatment of the Diabetic Neuropathy market.
There are several factors which are driving the market, like the surge in diabetic cases and the increase in the complications of disease because of age, inactive lifestyle and longer duration of Diabetes mellitus. The US has spent more than USD 966 Billion on healthcare related to Diabetes, and it has increased 316% in the last 15 years. There is a growth in the prevalence of Diabetic Foot Ulcers (DFU) along with large healthcare expenditures, expensive products and advanced treatment options. Due to the geriatric population, Diabetes is increasing at an unparalleled pace, broadly due to rapid urbanization, which leads to a more sedentary lifestyle. Diabetes is growing globally, and the patient numbers are estimated to become 643 million by 2030, and by 2045, it will become 784 million. In North America, it is estimated to reach 57 million in 2030, and by 2045, it will reach 63 million. Europe has a geriatric population, and hence, it is estimated that there will be around 67 million patients in 2030 and around 69 million in 2045. Presently, around 537 million adults are suffering from Diabetes globally. Peripheral neuropathy treatment is highly in demand. This is basically due to the ageing and obese population. Also, there is a surge in public knowledge towards peripheral neuropathy, which is also leading to the expansion of the market. Also, there are not many prescription medications for neuropathic pain, and hence, the market is largely dependent on the sales of off-label prescriptions. Drug target identification is complex, and the leading pharmaceutical organizations are working hard to manage the available treatment options. Transdermal medicines are broadly used for the treatment of neuropathic pain. Peripheral neuropathy occurs when the peripheral nerves are damaged, and this happens outside of the brain and spinal cord. This frequently leads to numbness, weakness and discomfort. These symptoms are generally felt in the hands and feet. Moreover, it might also affect several physiological functionalities such as urination, circulation and metabolism. Peripheral neuropathy also results in traumatic accidents, metabolic problems, infections, exposure to toxins or genetic factors. The main reason is Diabetes. Diabetic peripheral neuropathy shows the signs of peripheral nerve dysfunction in people having Diabetes after all the possibilities were excluded. It has been observed that many hospitals, clinics and ambulatory surgical centres are adopting advanced equipment and devices. The diabetic neuropathy sector is growing due to the growing prevalence of chronic diseases and advancement in the healthcare and medical sectors. There is growth in the adoption of advanced techniques and tools and an increase in funds by many private and public sectors. Moreover, there is more emphasis on precision medicine and the growing adoption of home care settings and point-of-care diagnostics. All these factors are driving the market.
Get an overview of this study by requesting a free sample
Increase in the obese population: The growing prevalence of diabetic neuropathy is broadly due to diabetic patients worldwide. The increase in the prevalence of diabetes is due to an increase in the sedentary lifestyle. Also, there is a growing obese population due to improper diet. Based on one of the studies in 2022, every one in 8 people globally is living with obesity. It has been observed that adult obesity has over doubled since 1990, and also adolescent obesity has quadrupled. In 2022, around 2.5 billion adults aged 18 years and more were found overweight, and in that, around 89o million were living with obesity. There is also a surge in awareness towards diagnosing and treating diabetes. Diabetic neuropathy happens to people suffering from diabetes. Nerves get damaged due to high blood glucose levels and fats in the body. All these factors are eventually driving the diabetic neuropathy market.
Alternative treatments: There are many alternative treatments, such as physiotherapy, meditation and massages. Physiotherapy helps people relieve pain and decrease numbness in the hands and legs. It also helps control blood sugar levels. Another study has also shown that exercise therapy helps in decreasing diabetes-related neuropathic pain, such as increased mechanical allodynia and thermal sensitivity. All these factors act as hindrances to the market.
Prevalence of chronic complications: Based on WHO estimates, around 51% of the people suffering from diabetes will eventually develop diabetic neuropathy. Diabetic peripheral neuropathy (DPN) is considered the most prevalent chronic complication of diabetes, and its prevalence is growing rapidly. It has been observed that the risk of diabetic peripheral neuropathy increases with age, and the lifetime prevalence is more than 50%. Recovery from diabetic neuropathy comes with prevention, change in lifestyle and altering risk factors. Some of the risk factors for peripheral neuropathy are long duration of diabetes, advanced age, poor glycemic control, smoking, hypertension, dyslipidemia and alcohol consumption. WHO report suggests that around 27% of diabetic patients have peripheral neuropathy, and more than 50% have developed injuries in the leg. Hence, there is a need for treatment. All these factors will drive the Diabetic Neuropathy in the forecasting period.
The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the largest market for the global Diabetic Neuropathy market, with a 40.03% share of the market revenue in 2023.
North America dominated the Diabetic Neuropathy sector, and this is due to the increasing number of patients who are getting treatment and diagnosis for diabetic neuropathy. The region also has government initiatives, such as funding research for new therapies and drugs. Also, most of the organizations that offer diabetes services are present in the US, which is home to around 72% of all global companies. Moreover, most of the R&D centres that research diabetes are present in the US, as it is the home of around 81% of all such analyzed R&D centres. All these factors are driving the Diabetic Neuropathy market in the region.
North America Region Diabetic Neuropathy Market Share in 2023 - 40.03%
www.thebrainyinsights.com
Check the geographical analysis of this market by requesting a free sample
The disorder type segment is divided into peripheral neuropathy, autonomic neuropathy, proximal neuropathy and focal neuropathy. The peripheral neuropathy segment dominated the market, with a market share of around 62.47% in 2023. This significant share is largely attributed to the fact that it is the most common form of diabetic neuropathy, which affects most diabetic patients. Peripheral neuropathy leads to weakness, numbness and discomfort. Its symptoms are largely felt in feet and hands.
The drug class segment is divided into non-steroidal anti-inflammatory drugs (NSAIDs), opioid, capsaicin, antidepressants and others. The non-steroidal anti-inflammatory drugs (NSAIDs) segment dominated the market, with a market share of around 40.33% in 2023. The substantial share is due to its broad use in diabetic neuropathy treatment as it helps in managing pain and is prescribed as the first line of treatment. NSAIDs reduce inflammation and decrease prostaglandin synthesis, which helps in alleviating pain and discomfort related to diabetic neuropathy. Also, NSAIDs are broadly available over the counter and more affordable in comparison to the treatment options.
The distribution channel segment is divided into hospital pharmacies, retail pharmacies, online and others. The hospital pharmacies segment dominated the market, with a market share of around 51.19% in 2023. The substantial share is due to a larger number of patients visiting hospitals; therefore, they prefer hospital pharmacies. Diabetic patients still prefer hospitals for their diagnosis as they have better infrastructure and facilities; hence, hospital pharmacies are largely used.
| Attribute | Description |
|---|---|
| Market Size | Revenue (USD Billion) |
| Market size value in 2023 | USD 4.17 Billion |
| Market size value in 2033 | USD 8.04 Billion |
| CAGR (2024 to 2033) | 6.8% |
| Historical data | 2020-2022 |
| Base Year | 2023 |
| Forecast | 2024-2033 |
| Region | The regions analyzed for the market are North America, Europe, South America, Asia Pacific, and Middle East & Africa. Furthermore, the regions are further analyzed at the country level. |
| Segments | Product Type, Source, Distribution Channel |
As per The Brainy Insights, the size of the Diabetic Neuropathy market was valued at USD 4.17 Billion in 2023 to USD 8.04 Billion by 2033.
Global Diabetic Neuropathy market is growing at a CAGR of 6.8% during the forecast period 2024-2033.
North America region emerged as the largest market for the Diabetic Neuropathy market.
1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis By Disorder Type
4.3.2. Market Attractiveness Analysis By Drug Class
4.3.3. Market Attractiveness Analysis By Distribution Channel
4.3.4. Market Attractiveness Analysis By Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. Increase in the obese population
5.3. Restraints
5.3.1. Alternative treatments
5.4. Opportunities
5.4.1. Prevalence of chronic complications
5.5. Challenges
5.5.1. Economic slowdown
6. Global Diabetic Neuropathy Market Analysis and Forecast, By Disorder Type
6.1. Segment Overview
6.2. Peripheral Neuropathy
6.3. Autonomic Neuropathy
6.4. Proximal Neuropathy
6.5. Focal Neuropathy
7. Global Diabetic Neuropathy Market Analysis and Forecast, By Drug Class
7.1. Segment Overview
7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
7.3. Opioid
7.4. Capsaicin
7.5. Antidepressants
7.6. Others
8. Global Diabetic Neuropathy Market Analysis and Forecast, By Distribution Channel
8.1. Segment Overview
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
8.4. Online
8.5. Others
9. Global Diabetic Neuropathy Market Analysis and Forecast, By Regional Analysis
9.1. Segment Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.5. South America
9.5.1. Brazil
9.6. Middle East and Africa
9.6.1. UAE
9.6.2. South Africa
10. Global Diabetic Neuropathy Market-Competitive Landscape
10.1. Overview
10.2. Market Share of Key Players in Global Diabetic Neuropathy Market
10.2.1. Global Company Market Share
10.2.2. North America Company Market Share
10.2.3. Europe Company Market Share
10.2.4. APAC Company Market Share
10.3. Competitive Situations and Trends
10.3.1. Product Launches and Developments
10.3.2. Partnerships, Collaborations, and Agreements
10.3.3. Mergers & Acquisitions
10.3.4. Expansions
11. Company Profiles
11.1. Pfizer. Inc
11.1.1. Business Overview
11.1.2. Company Snapshot
11.1.3. Company Market Share Analysis
11.1.4. Company Product Portfolio
11.1.5. Recent Developments
11.1.6. SWOT Analysis
11.2. Janssen Pharmaceuticals, Inc
11.2.1. Business Overview
11.2.2. Company Snapshot
11.2.3. Company Market Share Analysis
11.2.4. Company Product Portfolio
11.2.5. Recent Developments
11.2.6. SWOT Analysis
11.3. Abbott
11.3.1. Business Overview
11.3.2. Company Snapshot
11.3.3. Company Market Share Analysis
11.3.4. Company Product Portfolio
11.3.5. Recent Developments
11.3.6. SWOT Analysis
11.4. Eli Lilly and Company
11.4.1. Business Overview
11.4.2. Company Snapshot
11.4.3. Company Market Share Analysis
11.4.4. Company Product Portfolio
11.4.5. Recent Developments
11.4.6. SWOT Analysis
11.5. Novartis
11.5.1. Business Overview
11.5.2. Company Snapshot
11.5.3. Company Market Share Analysis
11.5.4. Company Product Portfolio
11.5.5. Recent Developments
11.5.6. SWOT Analysis
11.6. Lupin Pharmaceuticals
11.6.1. Business Overview
11.6.2. Company Snapshot
11.6.3. Company Market Share Analysis
11.6.4. Company Product Portfolio
11.6.5. Recent Developments
11.6.6. SWOT Analysis
11.7. Glenmark Pharmaceuticals Ltd
11.7.1. Business Overview
11.7.2. Company Snapshot
11.7.3. Company Market Share Analysis
11.7.4. Company Product Portfolio
11.7.5. Recent Developments
11.7.6. SWOT Analysis
11.8. Boehringer Ingelheim GmbH
11.8.1. Business Overview
11.8.2. Company Snapshot
11.8.3. Company Market Share Analysis
11.8.4. Company Product Portfolio
11.8.5. Recent Developments
11.8.6. SWOT Analysis
11.9. Astellas Pharma Inc
11.9.1. Business Overview
11.9.2. Company Snapshot
11.9.3. Company Market Share Analysis
11.9.4. Company Product Portfolio
11.9.5. Recent Developments
11.9.6. SWOT Analysis
List of Table
1. Global Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
2. Global Peripheral Neuropathy, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
3. Global Autonomic Neuropathy, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
4. Global Proximal Neuropathy, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
5. Global Focal Neuropathy, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
6. Global Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
7. Global Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
8. Global Opioid, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
9. Global Capsaicin, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
10. Global Antidepressants, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
11. Global Others, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
12. Global Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
13. Global Hospital Pharmacies, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
14. Global Retail Pharmacies, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
15. Global Anchovy, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
16. Global Online, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
17. Global Others, Diabetic Neuropathy Market, By Region, 2020-2033 (USD Billion)
18. North America Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
19. North America Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
20. North America Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
21. U.S. Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
22. U.S. Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
23. U.S. Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
24. Canada Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
25. Canada Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
26. Canada Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
27. Mexico Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
28. Mexico Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
29. Mexico Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
30. Europe Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
31. Europe Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
32. Europe Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
33. Germany Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
34. Germany Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
35. Germany Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
36. France Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
37. France Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
38. France Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
39. U.K. Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
40. U.K. Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
41. U.K. Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
42. Italy Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
43. Italy Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
44. Italy Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
45. Spain Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
46. Spain Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
47. Spain Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
48. Asia Pacific Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
49. Asia Pacific Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
50. Asia Pacific Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
51. Japan Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
52. Japan Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
53. Japan Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
54. China Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
55. China Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
56. China Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
57. India Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
58. India Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
59. India Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
60. South America Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
61. South America Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
62. South America Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
63. Brazil Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
64. Brazil Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
65. Brazil Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
66. Middle East and Africa Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
67. Middle East and Africa Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
68. Middle East and Africa Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
69. UAE Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
70. UAE Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
71. UAE Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
72. South Africa Diabetic Neuropathy Market, By Disorder Type, 2020-2033 (USD Billion)
73. South Africa Diabetic Neuropathy Market, By Drug Class, 2020-2033 (USD Billion)
74. South Africa Diabetic Neuropathy Market, By Distribution Channel, 2020-2033 (USD Billion)
List of Figures
1. Global Diabetic Neuropathy Market Segmentation
2. Global Diabetic Neuropathy Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Diabetic Neuropathy Market Attractiveness Analysis By Disorder Type
9. Global Diabetic Neuropathy Market Attractiveness Analysis By Drug Class
10. Global Diabetic Neuropathy Market Attractiveness Analysis By Distribution Channel
11. Global Diabetic Neuropathy Market Attractiveness Analysis By Region
12. Global Diabetic Neuropathy Market: Dynamics
13. Global Diabetic Neuropathy Market Share By Disorder Type (2023 & 2033)
14. Global Diabetic Neuropathy Market Share By Drug Class (2023 & 2033)
15. Global Diabetic Neuropathy Market Share By Distribution Channel (2023 & 2033)
16. Global Diabetic Neuropathy Market Share By Regions (2023 & 2033)
17. Global Diabetic Neuropathy Market Share By Company (2023)
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. The Brainy Insights has segmented the global Diabetic Neuropathy market based on below mentioned segments:
Global Diabetic Neuropathy Market by Disorder Type
Global Diabetic Neuropathy Market by Drug Class:
Global Diabetic Neuropathy Market by Distribution Channel:
Global Diabetic Neuropathy Market by Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Free Customization
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date
